Bashiru Ibrahim | Cancer Cells | Best Researcher Award

Published on by Oncology

Dr. Bashiru Ibrahim | Cancer Cells | Best Researcher Award

Research Fellow | University of Birmingham | United Kingdom

Dr. Bashiru Ibrahim is a highly skilled nanotoxicology and environmental science researcher with a strong academic foundation and extensive laboratory, teaching, and project management experience. He holds a PhD in Nanotoxicology from the University of Birmingham, where his research focused on the toxicological effects of metallic nanomaterials on lung epithelial cells, examining their interactions with cellular stress pathways, protein degradation systems, and intracellular uptake mechanisms. His academic journey also includes an MSc in Environmental Science with Distinction from the Islamic University in Uganda, where he studied the relationship between waterborne diseases and community water-handling practices, and a BSc in Biochemistry from Usmanu Danfodiyo University in Nigeria. Ibrahim has developed advanced expertise in nanomaterial synthesis, characterisation, cytotoxicity assays, flow cytometry, ICP-MS, confocal microscopy, and data analysis using multiple statistical software tools. He has worked as a Research Associate at the University of Birmingham, contributing to major international projects such as ACCORDs and NanoSolveIT, where he synthesised and characterised diverse nanomaterials, performed toxicological assessments using various cell lines and zebrafish models, and supported sustainable material design initiatives.

Citation Metrics (Google Scholar)

260

240

200

160

120

80

40

 

Citations
222
i10 Index
8
h-Index
9
        🟦 Citations          🟥I- 10 Index      🟩 h-index

View Google Scholar Profile

Featured Publications

Harini Keerthana SureshKumar | Cancer Cells | Best Researcher Award

Published on by Oncology

Ms. Harini Keerthana SureshKumar | Cancer Cells | Best Researcher Award 

PhD | Universitätsklinikum Heidelberg | Germany

Ms. Harini Keerthana SureshKumar is a dedicated biomedical scientist and emerging oncology researcher whose strong academic foundation and diverse research experience make her highly suitable for a Best Researcher Award. Currently pursuing her PhD in Anaesthesiology at Universitätsklinikum Heidelberg, she focuses on intraoperative cell salvage in oncological surgery while building on a solid background in molecular medicine and biomedical sciences. Her research journey includes extensive work in cell signaling, infection biology, microbial genomics, and cancer-related translational studies, supported by hands-on expertise in advanced laboratory techniques such as flow cytometry, immunoblotting, plasmid transfection, siRNA methodologies, viral assays, histology, microscopy, microbial culturing, genome analysis, and molecular diagnostics. She has contributed to impactful scientific literature, publishing in reputed journals including the European Journal of Surgical Oncology, Cell Communication and Signaling, Annals of Microbiology, Cells, and the Journal of Microbiology, Biotechnology and Food Sciences, along with depositing microbial genome sequences in the NCBI database. Ms. Harini has demonstrated research excellence through multiple roles as a research assistant and intern across prestigious German and Indian institutions, consistently applying complex methodologies to clinically relevant projects. Her academic achievements are complemented by recognition such as the Highly Recommended Poster Award at NATA’s 25th Anniversary Congress and winning the MIT COVID-19 Challenge in India. She has further strengthened her research competencies by completing specialized courses in microscopy, transgenic models, molecular intensive care, scientific ethics, and animal research regulations. Actively engaged in international conferences and scientific workshops, she reflects a strong commitment to innovation, collaboration, and scientific advancement. Alongside her technical abilities, she brings organizational strengths, problem-solving skills, and strong interpersonal capabilities, making her a promising young scientist with clear potential for significant future contributions to oncology and biomedical research.

Profile: ORCID

Featured Publications

  1. SureshKumar, H., Schenz, J., Waters, J. H., Weigand, M. A., Seyfried, T., Juratli, M. A., Frietsch, T., & Fischer, D. (2025). Revisiting the safety of intraoperative cell salvage in cancer surgery: How to evaluate the functional properties of remaining cancer cells. European Journal of Surgical Oncology. DOI: 10.1016/j.ejso.2025.110532

  2. Hornung, F., SureshKumar, H. K., Klement, L., Reisser, Y., Wernike, C., Nischang, V., Jordan, P. M., Werz, O., Hoffmann, C., Löffler, B., et al. (2025). High-fat diet impairs microbial metabolite production and aggravates influenza A infection. Cell Communication and Signaling. DOI: 10.1186/s12964-025-02367-w

  3. Hussain, I., Sureshkumar, H. K., Bauer, M., & Rubio, I. (2023). Starvation protects hepatocytes from inflammatory damage through paradoxical mTORC1 signaling. Cells, 12(12), 1668. DOI: 10.3390/cells12121668

  4. Suresh Kumar, H. K., Gopikrishna, T., Tapasya, K., Perumal, K., & Elavarashi, E. (2023). A computational genome analysis of strain Bacillus subtilis MIZ-8 isolated from Bekang reveals a distinct chromosome and plasmid conferring selective advantage. Journal of Microbiology, Biotechnology and Food Sciences, 13(2), e9141. DOI: 10.55251/jmbfs.9141

  5. Gopikrishna, T., Suresh Kumar, H. K., Perumal, K., & Elangovan, E. (2021). Impact of Bacillus in fermented soybean foods on human health. Annals of Microbiology, 71, 30. DOI: 10.1186/s13213-021-01641-9

Ms. Harini Keerthana SureshKumar’s research advances the safety and precision of cancer surgery while deepening scientific understanding of immune responses, microbial interactions, and cellular signaling. Her contributions support improved clinical outcomes, inform translational innovations, and strengthen global efforts in oncology, infectious disease biology, and patient-centered healthcare.

Luis Rico | Oncology | Editorial Board Member

Published on by Oncology

Dr. Luis Rico | Oncology | Editorial Board Member

Managing Director | Hospital Aleman | Argentina

Dr. Luis Rico is a distinguished clinician–researcher at Hospital Alemán, Buenos Aires, renowned for his impactful contributions to urology, with a strong focus on endourology, advanced laser technologies, and minimally invasive surgical innovation. His work centers on improving procedural precision, optimizing perioperative outcomes, and enhancing patient safety in the management of complex urolithiasis. By integrating next-generation laser systems, cutting-edge endoscopic platforms, and refined surgical protocols, Dr. Rico continually advances evidence-based approaches that elevate standards of clinical care. With an active and growing academic footprint, he has authored numerous peer-reviewed publications addressing pivotal challenges in intrarenal surgery, flexible ureteroscopy, and comparative laser performance particularly evaluating modalities such as the Thulium Fiber Laser and HO:YAG systems. His research has expanded global understanding of operative efficiency, stone-free rates, laser–tissue dynamics, and postoperative recovery pathways. Dr. Rico collaborates extensively with international urology organizations, multidisciplinary surgical teams, and multicenter research networks, underscoring his commitment to shared scientific progress, surgical innovation, and clinical excellence. In addition to his research, he plays a key role in clinical training, contributes to multicenter trials, and advances patient-centered care through methodical, outcomes-driven practice. His scholarly contributions reflect a balanced blend of innovation, scientific rigor, and translational relevance, ensuring continued impact on the evolving landscape of urologic surgery and minimally invasive therapeutic strategies. Dr. Rico’s academic influence is further highlighted by his research metrics, which include 252 citations, 35 scientific documents, and an h-index of 9, reflecting both the quality and reach of his contributions to modern urological science.

Profiles: Scopus | ORCID | ResearchGate

Featured Publications

Rico, L., Blas, L., Álvarez Jaramillo, J., Filgueira, G., Soldano, J., & Contreras, P. (2025). Magneto Ho:YAG laser versus Thulium Fiber Laser for laser lithotripsy during flexible ureteroscopy with a flexible and navigable ureteral access sheath. International Urology and Nephrology.

Rico, L., Blas, L., Banda Ramos, L., Maqueda, M., Pizzarello, J., & Contreras, P. (2025). Thulium Fiber Laser versus Vapor Tunnel HO:YAG laser in retrograde intrarenal surgery: Which one has better laser ablation performance? World Journal of Urology.

Rico, L., Diaz-Zorita, V., Blas, L., Banda Ramos, L., Sabeh, P., & Contreras, P. (2025). Is the ablation stone efficacy and efficiency better with a flexible and navigable suction ureteric access sheath? World Journal of Urology.

Rico, L., Blas, L., Pizzarello, J., Banda-Ramos, L., & Contreras, P. (2024). Mini-endoscopic combined intrarenal surgery (mini-ECIRS) for complex urolithiasis. World Journal of Urology.

Rico, L., Maqueda, M., Blas, L., & Contreras, P. (2024). Anterograde placement of drug-coated balloon for ureteroileal anastomosis stricture. BMJ Case Reports.

Shahanavaj Khan | Cancer Science | Editorial Board Member

Published on by Oncology

Assoc. Prof. Dr. Shahanavaj Khan | Cancer Science | Editorial Board Member

Associate Professor | Shri Ram College | India

Dr. Shahanavaj Khan is a distinguished researcher at King Saud University, Riyadh, specializing in cancer biology, pharmacology, and bioactive natural compounds. His work focuses on the anti-cancer and anti-inflammatory potential of plant-derived molecules, with particular emphasis on mechanisms involving apoptosis, Toll-Like Receptors, and microbiome-mediated cancer pathways. Dr. Khan employs advanced in-silico, in-vitro, and translational approaches to identify novel therapeutic targets and understand disease mechanisms, aiming to improve cancer diagnostics and treatment strategies. He has authored 54 publications in high-impact journals, contributing significantly to the understanding of prostate, lung, and other cancers, while integrating computational modeling with experimental validation. His research involves extensive collaborations with over 200 co-authors globally, demonstrating leadership in multidisciplinary oncology and pharmacology networks. Through his innovative studies on natural bioactive compounds and cancer therapeutics, Dr. Khan has contributed to the advancement of safer, more targeted treatment options, positively impacting patient care and public health. His scholarly work also underscores the importance of microbiome and receptor-mediated mechanisms in disease progression, bridging fundamental research with clinical applications. Dr. Khan’s academic influence and research productivity are reflected in his metrics 1,355 citations, 54 documents, and an h-index of 21.

Profiles: Scopus

Featured Publications

Khan, S., et al. (2025). Implication of Toll-Like Receptors in growth and management of health and diseases: Special focus as a promising druggable target to Prostate Cancer. [Review]. 7 citations.

Khan, S., et al. (2025). The implication of microbiome in lungs cancer: mechanisms and strategies of cancer growth, diagnosis and therapy. [Review]. 6 citations.

Khan, S., et al. (2025). Analysis of anti-cancer and anti-inflammatory activity in Typhonium flagelliforme rhizome extract by induction of apoptosis: An in-vitro study. Fitoterapia.

Jun Lu | Cancer | Editorial Board Member

Published on by Oncology

Prof. Jun Lu | Cancer | Editorial Board Member

Professor | Chengdu University of Traditional Chinese Medicine | China

Dr. Jun Lu is a distinguished researcher at Chengdu University of Traditional Chinese Medicine, China, specializing in cancer nanomedicine, biomaterials, and translational therapeutics. His work focuses on the design and development of multifunctional nanoplatforms, including engineered chitosan nanoparticles, aptamer-conjugated chemotherapeutics, and self-gelling biomaterials for applications in tumor therapy, wound healing, and infectious disease management. Dr. Lu integrates molecular biology, materials science, and bioengineering to advance innovative therapeutic strategies, such as modulating tumor microenvironments, orchestrating DNA damage pathways in colorectal carcinoma, and promoting MRSA-infected wound healing. He has authored 78 publications in high-impact journals including Journal of Translational Medicine, Chemical Engineering Journal, Carbohydrate Polymers, and Nano Research, reflecting strong expertise in nanobiotechnology and translational oncology. His extensive collaborations with over 380 co-authors worldwide demonstrate his leadership in multidisciplinary research networks, bridging fundamental science with clinical applications. Beyond academic contributions, Dr. Lu’s work has significant societal impact by enabling advanced therapies for cancer, infectious diseases, and tissue repair, providing novel solutions to global health challenges. His research emphasizes translational relevance and real-world applicability, contributing to safer, more effective, and innovative therapeutic modalities. Dr. Lu’s academic influence and research productivity are reflected in his metrics 2,421 citations, 78 documents, and an h-index of 24.

Profiles: Google Scholar | Scopus | ORCID 

Featured Publications

Lu, J., Zhang, H., Hou, J., Li, X., Hu, X., Hu, Y., Easton, C. D., Li, Q., Sun, C., … (2020). Efficient metal ion sieving in rectifying subnanochannels enabled by metal–organic frameworks. Nature Materials, 19(7), 767–774. Cited by: 495

Ni, S., Yao, H., Wang, L., Lu, J., Jiang, F., Lu, A., Zhang, G. (2017). Chemical modifications of nucleic acid aptamers for therapeutic purposes. International Journal of Molecular Sciences, 18(8), 1683. Cited by: 384

Lu, J., Jiang, F., Lu, A., Zhang, G. (2016). Linkers having a crucial role in antibody–drug conjugates. International Journal of Molecular Sciences, 17(4), 561. Cited by: 352

Tan, C. M., Therien, A. G., Lu, J., Lee, S. H., Caron, A., Gill, C. J., Lebeau-Jacob, C., … (2012). Restoring Methicillin-Resistant Staphylococcus aureus susceptibility to β-lactam antibiotics. Science Translational Medicine, 4(126), 126ra35.
Cited by: 328

Li, F., Lu, J., Liu, J., Liang, C., Wang, M., Wang, L., Li, D., Yao, H., Zhang, Q., Wen, J., … (2017). A water-soluble nucleolin aptamer-paclitaxel conjugate for tumor-specific targeting in ovarian cancer. Nature Communications, 8(1), 1390.
Cited by: 275

 

Ramon Mangues | Cancer | Best Research Article Award

Published on by Oncology

Prof. Dr. Ramon Mangues | Cancer | Best Research Article Award

Pharmacological Research | Institut de Recerca Sant Pau | Spain

Prof. Dr. Ramon Mangues Bafalluy, PharmD, PhD, is a distinguished Clinical Pharmacist and Biomedical Research Professor at the Institut de Recerca, Hospital de la Santa Creu i Sant Pau, where he leads the Consolidated Oncogenesis and Antitumor Drugs Group (GOA). A recognized authority in oncology, nanomedicine, and targeted drug delivery, he has made pioneering contributions to the development of therapeutic nanotechnologies and translational cancer research. Trained in pharmacy and clinical pharmacology, Dr. Mangues advanced his expertise in cancer biology through extensive postdoctoral research at the New York University Medical Center. His professional career spans key leadership roles within IIB Sant Pau, CIBER-BBN, and as Co-founder and Scientific Advisor of Nanoligent S.L., a spin-off dedicated to translating nanomedicine discoveries into clinical therapies. His research interests encompass nanoconjugates, protein-based nanoparticles for targeted drug delivery, immunotherapeutic strategies, preclinical drug development, and biomarker identification for improved cancer diagnosis and treatment. A strong advocate of collaborative science, he has partnered with leading clinical specialists and secured numerous competitive research grants, including participation in major European Union initiatives such as SAFE-N-MEDTECH, EuroTransBio, and H2020 programs. Holding multiple patents in nanomedicine, Dr. Mangues’s innovative work bridges the gap between molecular oncology and clinical application. As a mentor and academic leader, he has supervised numerous doctoral theses and authored an extensive body of publications that have shaped contemporary cancer nanotherapy approaches. His achievements have been recognized through prestigious distinctions for research excellence and international scientific leadership. Dr. Mangues’s enduring impact on biomedical innovation is evident through 7,280 citations, 154 documents, and an h-index of 42, underscoring his influential role in advancing nanomedicine and targeted cancer therapy research.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Merlos-Suárez, A., Barriga, F. M., Jung, P., Iglesias, M., Céspedes, M. V., Rossell, D., Sevillano, M., Attolini, C. S.-O., Hernando-Momblona, X., da Silva-Diz, V., Muñoz, P., Clevers, H., Sancho, E., Mangues, R., & Batlle, E. (2011). The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell, 8(5), 511–524. Cited by: 1,145

2. Sanchez-Garcia, L., Martín, L., Mangues, R., Ferrer-Miralles, N., Vázquez, E., & Villaverde, A. (2016). Recombinant pharmaceuticals from microbial cells: A 2015 update. Microbial Cell Factories, 15(1), 33. Cited by: 445

3. Esteller, M., Gonzalez, S., Risques, R. A., Marcuello, E., Mangues, R., Germa, J. R., Herman, J. G., Capellà, G., & Peinado, M. A. (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology, 19(2), 299–304. Cited by: 335

4. Guerrero, S., Casanova, I., Farré, L., Mazo, A., Capellà, G., & Mangues, R. (2000). K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene. Cancer Research, 60(23), 6750–6756. Cited by: 325

5. Ventura, S., Zurdo, J., Narayanan, S., Parreño, M., Mangues, R., Reif, B., Chiti, F., Giannoni, E., Dobson, C. M., & Serrano, L. (2004). Short amino acid stretches can mediate amyloid formation in globular proteins: The Src homology 3 (SH3) case. Proceedings of the National Academy of Sciences, 101(19), 7258–7263. Cited by: 301

Rami Ahmad | Cancer Therapy | Best Researcher Award

Published on by Oncology

Prof. Dr. Rami Ahmad | Cancer Therapy | Best Researcher Award

Senior Researcher | Czech Education and Scientific Network | Czech Republic

Prof. Dr. Rami Ahmad El-Nabulsi is a distinguished theoretical physicist and applied mathematician whose research bridges nonlinear quantum dynamics, fractal mechanics, plasma and solid-state physics, and advanced mathematical modeling. Holding a PhD in Particle and Mathematical Physics from AMU, along with postgraduate diplomas in Plasma Physics and degrees in Physics at both master’s and bachelor’s levels, he has built a prolific career combining theoretical rigor with computational innovation. He is currently affiliated with the Center of Excellence in Quantum Technology, Faculty of Engineering, and the Quantum-Atom Optics Laboratory at Chiang Mai University, Thailand, as well as with the University of South Bohemia and the Department of Optical Networks CESNET in the Czech Republic. Prof. El-Nabulsi’s research interests encompass geometrical and quantum dynamics, nonlinear systems, chaos and bifurcations, general relativity, quantum field theory, and the application of fractional and fractal calculus to complex systems in engineering, astrophysics, and materials science. His expertise extends to advanced computational modeling, partial differential equations, stochastic systems, and numerical simulations. He has received multiple international honors, including the Outstanding Scientist Research Award and the Lifetime Achievement Award. A reviewer for more than 250 scientific journals and an editorial board member in over 40 peer-reviewed publications, he has authored more than 390 research articles in high-impact international journals and is frequently invited as an honorary speaker at global conferences. Prof. El-Nabulsi’s academic dedication, multidisciplinary approach, and sustained research excellence continue to shape theoretical and applied physics worldwide. His scholarly impact is reflected in 4,873 citations, 277 documents, and an h-index of 35, underscoring his influential role in advancing modern fractal physics and nonlinear dynamical systems research.

Profiles: Google Scholar | Scopus | ORCID 

Featured Publications

1. El-Nabulsi, R. A., & Anukool, W. (2025). Chaotic and fractal maps in higher-order derivative dynamical systems. Frontiers in Physics, 12, 1529644. Cited by: 8

2. El-Nabulsi, R. A., & Anukool, W. (2025). Qualitative financial modelling in fractal dimensions. Financial Innovation, 11, 42. Cited by: 6

3. El-Nabulsi, R. A. (2025). A fractional model to study soliton in presence of charged space debris at low-Earth orbital plasma region. IEEE Transactions on Plasma Science, 52(9), 4671–4693. Cited by: 4

4. El-Nabulsi, R. A., & Golmankhaneh, A. K. (2025). Propagation of waves in fractal spaces. Waves in Random and Complex Media. Cited by: 4

5. El-Nabulsi, R. A., & Anukool, W. (2025). Vlasov equation, waves and dispersion relations in fractal dimensions: Landau damping and the toroidal ion temperature gradient instability problem. Waves in Random and Complex Media. Cited by: 14

6. El-Nabulsi, R. A. (2024). Transition from circular to spiral waves and from Mexican hat to upside-down Mexican hat-solutions: The cases of local and nonlocal λ–ω reaction–diffusion–convection fractal systems with variable coefficients. Chaos, Solitons & Fractals, 189, 115737. Cited by: 3

7. El-Nabulsi, R. A. (2024). Modelling nematic liquid crystal in fractal dimensions. Medicine in Novel Technology and Devices, 24, 100334. Cited by: 7